Tyrosine News and Research

RSS

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

A 36-week screening strategy safely reduces pre-eclampsia at term

Screening pregnant women at 36 weeks using a validated risk model and offering risk-stratified planned early-term birth reduced the incidence of term pre-eclampsia by about 30 percent without increasing maternal or neonatal complications. The randomised PREVENT-PE trial demonstrates that a personalised timing-of-birth strategy can prevent term pre-eclampsia where no effective medical prevention currently exists.

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

7 Dec 2025

AI model ranks genetic variants from severe to mild disease mutations

popEVE combines evolutionary insights with human population data to identify damaging genetic mutations, improving variant scoring for rare diseases.

3 Dec 2025

UBQLN2 liquid droplets emerge as key catalysts of early α-synuclein aggregation

Parkinson's disease (PD) is an age-related, progressive neurodegenerative disorder. The hallmark of PD pathogenesis is the Lewy bodies (LBs) that accumulate in neurons in the substantia nigra region of the brain, damaging these neurons and leading to the motor symptoms of the disease.

26 Nov 2025

DeepTarget tool uncovers primary and secondary drug targets across cancer types

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

18 Nov 2025

DeepTarget: A new tool for drug repurposing in oncology

14 Nov 2025

High protein breakfasts help you feel fuller but do not change how much you eat later

High protein breakfasts, whether plant or animal-based, boosted GLP-1 and PYY and modestly reduced appetite compared with a low protein, high carbohydrate meal. Despite these hormonal and appetite changes, lunchtime energy intake remained unchanged in both younger and older adults.

13 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

New NIH grants fuel research in oral cancer treatment and pain relief

Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, have been awarded three multi-year grants totaling $6 million from the National Institutes of Health to address treatment and pain management for oral cancer.

7 Nov 2025

Comprehensive kinase atlas reveals new insights into cell signaling and disease

The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme's "tail" called phosphorylation patterns.

7 Nov 2025

Alzheimer’s breakthrough reveals how tweaking one gene shields brain connections

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid, blocks tau spread, and preserves synapses in Alzheimer’s disease. Microglial CD28 signaling helps restrain inflammation, revealing a regulatory switch that may inform future immunotherapies targeting microglia rather than neurons.

6 Nov 2025

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton's tyrosine kinase inhibitors (BTKi).

6 Nov 2025

Sensory effects of flavanols trigger physiological responses in the brain

Astringency is a dry, puckering, rough, or sandpapery sensation in the mouth caused by plant-derived polyphenols.

31 Oct 2025

Eating peanuts while pregnant may influence how a child’s genes respond to breastfeeding

Maternal peanut and peanut butter consumption during pregnancy and breastfeeding shaped DNA methylation patterns in children, particularly in genes regulating neurodevelopment and inflammation. These findings suggest maternal diet can prime offspring epigenetic sensitivity to breastfeeding duration.

27 Oct 2025

Tyrosine News and Research

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

A 36-week screening strategy safely reduces pre-eclampsia at term

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

AI model ranks genetic variants from severe to mild disease mutations

UBQLN2 liquid droplets emerge as key catalysts of early α-synuclein aggregation

DeepTarget tool uncovers primary and secondary drug targets across cancer types

DeepTarget: A new tool for drug repurposing in oncology

High protein breakfasts help you feel fuller but do not change how much you eat later

St. Jude study maps treatment strategy for rare infant gliomas

New NIH grants fuel research in oral cancer treatment and pain relief

Comprehensive kinase atlas reveals new insights into cell signaling and disease

Alzheimer’s breakthrough reveals how tweaking one gene shields brain connections

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Sensory effects of flavanols trigger physiological responses in the brain

Eating peanuts while pregnant may influence how a child’s genes respond to breastfeeding

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News